{
    "nct_id": "NCT03353740",
    "official_title": "Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence",
    "inclusion_criteria": "Inclusion Criteria\n\n* Histopathologically proven prostate adenocarcinoma.\n* Rising prostate-specific antigen (PSA) (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n  * Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation for biochemical recurrence after radical prostatectomy\n\n    * PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.\n  * Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy\n\n    * Nadir + greater than or equal to 2 ng/mL rise in PSA\n* Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).\n* Age >= 18.\n* Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria\n\n* Unable to lie flat, still or tolerate a PET scan.\n* Concomitant investigational therapy.\n* Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.\n* Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}